Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Patient
100%
Non Small Cell Lung Cancer
84%
Lung Cancer
42%
Programmed Death 1 Ligand 1
37%
Overall Survival
30%
Lung Adenocarcinoma
28%
Programmed Cell Death
25%
Neoplasm
24%
Epidermal Growth Factor Receptor
23%
Immune Checkpoint Inhibitor
22%
Surgery
21%
Ligand
20%
Adenocarcinoma
19%
Nutritional Status
18%
Inpatient
16%
Pneumonectomy
16%
Recurrence Free Survival
14%
Prognostic Factor
14%
Smoking
13%
Small Cell Lung Cancer
12%
Recurrent Disease
12%
Survival
11%
Therapeutic Procedure
11%
Disease Free Survival
10%
Skeletal Muscle
10%
Association
10%
Predictor
10%
Albumin
10%
C Reactive Protein
10%
Hazard Ratio
9%
Lobectomy
9%
Geriatrics
8%
Biological Marker
8%
Nivolumab
8%
Computer Assisted Tomography
8%
Analysis
8%
Serum
7%
Cells
7%
Chemoimmunotherapy
7%
Diagnosis
7%
Atezolizumab
7%
Multivariate Analysis
6%
Adverse Event
6%
Lesion
6%
Retrospective Study
6%
Squamous Cell Lung Carcinoma
6%
Monotherapy
6%
Metastatic Carcinoma
6%
Lymphocyte
6%
Prognosis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
20%
Ligand
15%
Programmed Death 1 Ligand 1
10%
Immune Checkpoint Inhibitor
9%
Lung Cancer
9%
Prognosis
8%
Non Small Cell Lung Cancer
8%
Programmed Cell Death
8%
Albumin
7%
Atezolizumab
7%
Lung Adenocarcinoma
7%
Neoplasm
7%
Adverse Event
6%
Adenocarcinoma
6%
Overall Survival
6%
C Reactive Protein
6%
Survival
5%
Lung Adenocarcinoma
5%
Nivolumab
5%